Company / PP&E (Net)
AXIM BIOTECHNOLOGIES, INC. PP&E (Net) History
FY2015-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$134.1K
FY2023
5-year range
$5.6K / $134.1K
FY2019-FY2023
Trend
+42.9%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $5,593 to $134,067 over the past 5 years.
Based on SEC 10-K filings.
$134,067 in FY2023 with a 5-year CAGR of +88.8%.
Improved from $5,593 to $134,067 over the past 5 years.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- +88.8%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +88.8%, indicating consistent growth.
- In FY2023, pp&e (net) increased 42.9% year-over-year.
- Lowest pp&e (net) in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -18.18 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2023 | $134.1K | +42.9% |
| FY2022 | $93.8K | +1577.8% |
| FY2018 | $5.6K | -37.5% |
| FY2017 | $8.9K | -27.3% |
| FY2016 | $12.3K | -21.4% |
| FY2015 | $15.7K | - |
| FY2013 | - | - |
| FY2012 | - | - |
| FY2011 | - | - |
As of FY2023 · SEC 10-K · Updated Jun 29, 2026